

## 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Anker Stefan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Aveo Oncology : Cachexia (2014)</li> <li>- PsiOxus Therapeutics : Cachexia therapy in cancer (2014)</li> <li>- Abbott Vascular : Device heart failure (2014)</li> <li>- Medtronic : DSMB (2014)</li> <li>- Luitpold : Heart failure (2014)</li> <li>- Cardiomems : Heart failure (2014)</li> <li>- Medical Sensible : Heart failure (2014)</li> <li>- Cardioxyl : Heart failure (2014)</li> <li>- Cardio3Bio : Heart failure (2014)</li> <li>- PharmaGenesis : Medical Writing Support (2014)</li> <li>- Metabolic Research srl (Italy) : Nutrition for Muscle Wasting / Cachexia (2014)</li> <li>- Cardiokinetix : SAB heart failure (2014)</li> <li>- BRAHMS GmbH : Biomarker in heart failure (2014-2015)</li> <li>- Impulse Dynamics : Device in heart failure (2014-2015)</li> <li>- Lonestar Heart : Device in heart failure (2014-2015)</li> <li>- Servier : Heart failure (2014-2015)</li> <li>- Biotronik : Heart failure (2014-2015)</li> <li>- Bayer AG : Heart failure (2014-2015)</li> <li>- ZS Pharma : Heart failure (2014-2015)</li> <li>- Vifor International : iv Iron therapy for heart failure (2014-2015)</li> <li>- Relypsa : K+ Resin (2014-2015)</li> <li>- Novartis : SAB heart failure (2014-2015)</li> </ul>

## 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Anker Stefan	<ul style="list-style-type: none"> <li>- Bioventrix : SAB in heart failure (2014-2015)</li> <li>- Respicardia : SAB phrenic nerve stimulation (2014-2015)</li> <li>- Pluristem Therapeutics : stem cells for muscle wasting &amp; critical limb ischemia (2014-2015)</li> <li>- Cardioentis : TRUE-AHF trial, executive committee (2014-2015)</li> <li>- Boehringer-Ingelheim : Heart failure (2015)</li> <li>- Sorin Group : SAB phrenic nerve stimulation (2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Metabolic Research srl (Italy) : Cachexia nutrition research (2014)</li> <li>- Aveo Oncology : Cachexia Research (2014)</li> <li>- Vifor International : CHF therapy development (2014)</li> <li>- Bayer AG : CHF therapy development (2014)</li> <li>- Abbott Vascular : Heart failure (2014)</li> <li>- Vifor International : CHF therapy development, FAIR-HFpEF (2015)</li> <li>- Abbott Vascular : Heart failure, RESHAP-HF2 (2015)</li> </ul>
Bueno Hector	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer Healthcare : Aspirin, rivaroxaban (2014)</li> <li>- Menarini : Ranolazine (2014)</li> <li>- Novartis : Serelaxin (2014)</li> <li>- Pfizer : Apixaban (2014-2015)</li> <li>- Bristol Myers Squibb : Apixaban (2014-2015)</li> <li>- Sanofi Aventis : Clopidogrel (2014-2015)</li> <li>- Servier : ivabradine (2014-2015)</li> <li>- Daiichi Sankyo : Prasugrel (2014-2015)</li> </ul>

## 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Bueno Hector	<ul style="list-style-type: none"> <li>- Eli Lilly : Prasugrel (2014-2015)</li> <li>- Astra Zeneca : Ticagrelor (2014-2015)</li> <li>- Bayer Healthcare : Aspirin (2015)</li> <li>- Novartis : Serelaxin, LCZ696 (2015)</li> <li>- Ferrer Internacional : Trinomia (polypill) (2015)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Ticagrelor (2015)</li> </ul> <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Ticagrelor (2014-2015)</li> </ul>
Cleland John	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Philips : Cardiac Imaging (2014-2015)</li> <li>- Amgen : Heart Failure (2014-2015)</li> <li>- Medtronic : Heart Failure (2014-2015)</li> <li>- Novartis : Heart Failure (2014-2015)</li> <li>- Sorin Group : Heart failure (2014-2015)</li> <li>- Johnson &amp; Johnson : Heart Failure (2014-2015)</li> <li>- Vifor International : Heart Failure (2014-2015)</li> <li>- Zoll Medical : Heart Failure (2014-2015)</li> <li>- Trevena : Heart Failure (2014-2015)</li> <li>- Stealthpeptides : Heart Failure (2014-2015)</li> <li>- Actelion : Pulmonary Hypertension (2014-2015)</li> <li>- Servier : Heart Failure (2015)</li> <li>- Bayer Healthcare : Heart Failure (2015)</li> <li>- Roche Diagnostics : Heart Failure (2015)</li> </ul>

## 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Cleland John	<ul style="list-style-type: none"> <li>- Sensible Medical : Heart Failure (2015)</li> <li>- ZS Pharma : Heart failure (2015)</li> <li>- Corvedia : Heart Failure (2015)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Amgen : Heart Failure (2014-2015)</li> <li>- Novartis : Heart failure (2014-2015)</li> <li>- Philips : Heart Failure (2014-2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Amgen : Heart Failure (2014-2015)</li> <li>- Novartis : Heart Failure (2014-2015)</li> <li>- Philips : Heart Failure (2014-2015)</li> <li>- Alere : Heart failure (2015)</li> <li>- Roche Diagnostics : Heart Failure (2015)</li> <li>- Thermofisher : Heart Failure (2015)</li> </ul>
Coats Andrew	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Menarini : Heart Failure (2014)</li> <li>- PsiOxus : Cancer (2014-2015)</li> <li>- Impulse Dynamics : Heart Failure (2014-2015)</li> <li>- Elsevier : Publishing (2014-2015)</li> <li>- Respicardia : Sleep Apnoea (2014-2015)</li> <li>- Servier : Heart Failure (2015)</li> <li>- Resmed : Sleep Apnoea (2015)</li> </ul> <p>C - Receipt of royalties for intellectual property.</p> <ul style="list-style-type: none"> <li>- Imperial College, London : Cancer (2014-2015)</li> </ul>

## 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Falk Volkmar	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Berlin Heals : cell modification (2014-2015)</li> <li>- Boston Scientific : heart valves (2014-2015)</li> <li>- Edwards Lifesciences : heart valves (2014-2015)</li> <li>- Medtronic : heart valves (2014-2015)</li> <li>- Aesculap : minimally invasive mitral surgery (2014-2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Philips : Imaging (2014-2015)</li> <li>- Heartware : LVAD (2014-2015)</li> </ul>
Gonzalez Juanatey Jose Ramon	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Kowa : Speaker fee (2014-2015)</li> <li>- Boehringer-Ingelheim : Speaker fee, AB (2014-2015)</li> <li>- Servier : Speaker fee, AB (2014-2015)</li> <li>- Bayer Healthcare : Speaker fee, AB (2014-2015)</li> <li>- Roche Pharma : Speaker fee, AB (2014-2015)</li> <li>- Esteve : Speaker fee, AB (2014-2015)</li> <li>- Almirall Spain : Speaker fee, AB (2014-2015)</li> <li>- Merck Sharp &amp; Dohme : Speaker fee, AB (2014-2015)</li> </ul>
Harjola Veli-Pekka	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Novartis : Acute heart failure (2014)</li> <li>- Servier : Chronic heart failure (2014)</li> <li>- Resmed : Sleep apnea (2014)</li> <li>- Bayer : Antithrombotic drugs (2014-2015)</li> <li>- Boehringer-Ingelheim : Antithrombotic drugs (2014-2015)</li> </ul>

## 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Harjola Veli-Pekka	<ul style="list-style-type: none"> <li>- Pfizer : Antithrombotic drugs (2014-2015)</li> <li>- Novartis : heart failure (2015)</li> <li>- Servier : heart failure (2015)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer : heart failure (2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Novartis : Acute heart failure (2014)</li> <li>- Orion : Acute heart failure (2014)</li> <li>- Servier : Chronic heart failure (2014)</li> <li>- Abbott Laboratories : laboratory diagnostics (2015)</li> </ul>
Jankowska Ewa Anita	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Pfizer : eplerenone in heart failure (2014)</li> <li>- Servier : heart rate control in CVD (2014)</li> <li>- Vifor International : i.v. iron (2014)</li> <li>- Novartis : treatment of acute heart failure (2014)</li> <li>- Pfizer : atorvastatin (2015)</li> <li>- Polpharma : cv drugs (2015)</li> <li>- Fresenius Nutrition : Distribution of iv iron in Poland (2015)</li> <li>- Axon Communications : Educational online materials on iv iron in CV diseases (2015)</li> <li>- Vifor Pharma : iv iron in heart failure and cv diseases (2015)</li> <li>- Servier : Ivabradine, heart failure (2015)</li> <li>- Novartis : LCZ696 (2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Vifor International : i.v. iron (2014)</li> </ul>

## 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Jankowska Ewa Anita	<ul style="list-style-type: none"> <li>- National Center for Science in Poland (governmental funding) : iron metabolism in heart failure (2015)</li> <li>E - Research funding (personal).               <ul style="list-style-type: none"> <li>- National Center for Science in Poland (governmental funding) : iron metabolism in heart failure (2015)</li> </ul> </li> </ul>
Jessup Mariell	<ul style="list-style-type: none"> <li>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</li> <li>- UpToDate : general medical reference-on line; I serve as topic area editor (2014-2015)</li> </ul>
Linde Cecilia	<ul style="list-style-type: none"> <li>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</li> <li>- Cardiomems : heart failure monitoring company now owned by St Jude (2014)</li> <li>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</li> <li>- Medtronic : CRT (2014-2015)</li> <li>D - Research funding (departmental or institutional).               <ul style="list-style-type: none"> <li>- Medtronic : CRT (2014-2015)</li> <li>- Cardio3 Biosciences : Stemcells (2014-2015)</li> <li>- Astra Zeneca : Heart failure epidemiology trial (2015)</li> <li>- Novartis : speaker honorarium (2015)</li> <li>- Biotronik : speaker honorarium (2015)</li> <li>- Impulse Dynamics : speaker honorarium (2015)</li> <li>- Vifor International : speaker honorarium (2015)</li> </ul> </li> </ul>
Nihoyannopoulos Petros	Nothing to be declared (2014-2015)
Parissis John T	<ul style="list-style-type: none"> <li>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</li> <li>- Novartis, Servier : heart failure (2014)</li> <li>- Roche Diagnostics : Biomarkers (2015)</li> <li>- Novartis : Cardiovascular (2015)</li> <li>- Pfizer : Cardiovascular (2015)</li> <li>- Servier : Cardiovascular (2015)</li> <li>- Menarini : Cardiovascular (2015)</li> <li>- Orion Pharma : Cardiovascular (2015)</li> </ul>

## 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Pieske Burkert	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Stealth Peptides : Acute coronary Syndrome, Heart Failure (2014)</li> <li>- Boehringer-Ingelheim : Anticoagulation (2014)</li> <li>- Daiichio-Sankyo : Anticoagulation (2014)</li> <li>- Astra-Zeneca : Antithrombotics (2014)</li> <li>- Novartis : Heart Failure (2014)</li> <li>- Servier : Heart Failure (2014)</li> <li>- Bayer Healthcare : Heart Failure, Pulmonary Hypertension (2014)</li> <li>- Astra Zeneca : Acute coronary syndrome (2015)</li> <li>- Bristol Myers Squibb : Diabetes, Hypertension (2015)</li> <li>- Bayer Healthcare : Heart Failure (2015)</li> <li>- Novartis : Heart Failure, Hypertension (2015)</li> <li>- Stealth Peptides : Heart Failure, Rare diseases (2015)</li> <li>- Abbott Vascular : Structural Interventions (2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Bayer Healthcare : Heart Failure (2014)</li> <li>- Biotronik : Structural intervention, electrophysiology (2015)</li> </ul>
Ponikowski Piotr	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : acute coronary syndrome (2014)</li> <li>- Boehringer-Ingelheim : anticoagulant (2014)</li> <li>- Respicardia : anticoagulant (2014)</li> <li>- Johnson &amp; Johnson : heart failure (2014)</li> <li>- Pfizer : heart failure, anticoagulant (2014)</li> <li>- MSD : lipids (2014)</li> </ul>



## 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Ponikowski Piotr	<ul style="list-style-type: none"> <li>- Abbott Vascular : devices (2014-2015)</li> <li>- Novartis : heart failure (2014-2015)</li> <li>- Cardiorentis : heart failure (2014-2015)</li> <li>- Bayer Healthcare : heart failure (2014-2015)</li> <li>- Vifor Pharma ltd : heart failure (2014-2015)</li> <li>- CIBIEM : heart failure (2014-2015)</li> <li>- Servier : heart failure, coronary artery disease (2014-2015)</li> <li>- Amgen : heart failure, lipids (2014-2015)</li> <li>- Boehringer-Ingelheim : anticoagulant, diabetes (2015)</li> <li>- Respicardia : devices (2015)</li> <li>- BioControl : devices (2015)</li> <li>- DC Device : devices (2015)</li> <li>- Celladon : heart failure (2015)</li> <li>- Pfizer : lipids (2015)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : acute coronary syndrome (2014)</li> <li>- Vifor Pharma ltd : heart failure (2014)</li> <li>- MSD : lipids (2014)</li> <li>- Respicardia : anticoagulant (2014-2015)</li> <li>- Novartis : heart failure (2014-2015)</li> <li>- Cardiorentis : heart failure (2014-2015)</li> <li>- Bayer Healthcare : heart failure (2014-2015)</li> <li>- CIBIEM : heart failure (2014-2015)</li> </ul>

## 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Ponikowski Piotr	<ul style="list-style-type: none"> <li>- Servier : heart failure, coronary artery disease (2014-2015)</li> <li>- Amgen : heart failure, lipids (2014-2015)</li> <li>- BioControl : devices (2015)</li> <li>- DC Device : devices (2015)</li> <li>- Celladon : heart failure (2015)</li> </ul>
Riley Jillian	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Novartis : invited speaker, advisory boards heart failure (2014)</li> <li>- Novartis : Cardiovascular (2015)</li> </ul>
Rosano Giuseppe M C	Nothing to be declared (2014-2015)
Ruilope Luis Miguel	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Instituto de Salud Carlos III. Ministerio de Economía y Competitividad. Gobierno de España : Albuminuria during chronic RAAS suppression (2014)</li> <li>- Daiichi Sankyo : Arterial Hypertension (2014)</li> <li>- Menarini : Arterial Hypertension (2014)</li> <li>- Esteve : Arterial Hypertension (2014)</li> <li>- Novartis : Arterial Hypertension &amp; CKD (2014)</li> <li>- Relypsa : CKD (2014)</li> <li>- Bayer AG : Finerenone (2014)</li> <li>- St Jude Medical : Renal Denervation (2014)</li> <li>- Astra Zeneca : Diabetes (2014-2015)</li> <li>- Sanofi Aventis : Lipids (2014-2015)</li> <li>- Medtronic : Renal denervation (2014-2015)</li> <li>- Novartis : CKD, HYPERTENSION (2015)</li> <li>- Bayer : FINERENONE TRIALS (2015)</li> </ul>

## 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Ruilope Luis Miguel	<ul style="list-style-type: none"> <li>- Instituto de Salud Carlos III. Ministerio de Economía y Competitividad. Gobierno de España : GRANT (2015)</li> <li>- Daiichi Sankyo : HYPERTENSION (2015)</li> <li>- Servier : HYPERTENSION (2015)</li> <li>- Amgen : LIPID DISORDERS (2015)</li> <li>- Relypsa : PATIROMER (2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Instituto de Salud Carlos III. Ministerio de Economía y Competitividad. Gobierno de España : Albuminuria during chronic RAAS suppression (2014)</li> <li>- Instituto de Salud Carlos III. Ministerio de Economía y Competitividad. Gobierno de España : OMICS (2015)</li> </ul>
Ruschitzka Frank	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Servier : Drugs (2014-2015)</li> <li>- Sanofi Aventis : Drugs (2015)</li> <li>- Zoll Medical : LifeVest (2015)</li> <li>- Heartware : Ventricular assist devices (2015)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer : Postgraduate Heart Failure Course (Grant to Zurich Heart House) (2014-2015)</li> <li>- Novartis : Postgraduate Heart Failure Course (Grant to Zurich Heart House) (2014-2015)</li> <li>- St Jude Medical : Postgraduate Heart Failure Course (Grant to Zurich Heart House) (2014-2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Mars : Flavanol-like cocoa products (2014-2015)</li> </ul>
Rutten Frans Hendrik	<p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : Atrial fibrillation (2014-2015)</li> </ul>
Van Der Meer Peter	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Resmed : ASV (2014-2015)</li> <li>- Singulex : biomarkers (2014-2015)</li> <li>- Vifor International : iron iv. (2014-2015)</li> </ul>

## 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Van Der Meer Peter	<ul style="list-style-type: none"> <li>- Servier : ivabradine (2014-2015)</li> <li>- Novartis : lcz 696 AND serelaxin (2014-2015)</li> <li>- Astra Zeneca : ZS-pharma hyperkalemia (2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Vifor International : iron deficiency in heart failure (2014-2015)</li> </ul>
Voors Adriaan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Nephera : device (urinary catheter) (2014)</li> <li>- Celladon : Mydicar (Heart Failure) (2014)</li> <li>- Singulex : biomarkers (2014-2015)</li> <li>- Cardio3 Biosciences : C3S-CQS (Heart Failure) (2014-2015)</li> <li>- Vifor International : Ferric Carboxymaltose (Heart Failure) (2014-2015)</li> <li>- Bayer Healthcare : Finerenone (Heart Failure) (2014-2015)</li> <li>- Servier : Ivabradine (Heart Failure) (2014-2015)</li> <li>- Merck Sharp &amp; Dohme : no product; speaker fees; Heart Failure (2014-2015)</li> <li>- Amgen : Omecamtic (Heart Failure) (2014-2015)</li> <li>- Novartis : Serelaxin/Aliskiren (Heart Failure) (2014-2015)</li> <li>- Trevena : TRV027 (Heart Failure) (2014-2015)</li> <li>- Stealth : Bendavia drug development in heart failure (2015)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer Healthcare : Partial adenosine A1-agonist (2014-2015)</li> <li>- Vifor Pharma : Speaker fees: Heart Failure (2014-2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Novartis : Heart Failure (2014)</li> <li>- Singulex : Biomarkers in Heart Failure (2014-2015)</li> </ul>

## 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Voors Adriaan	<ul style="list-style-type: none"> <li>- Servier : EDIFY study with Ivabrainine in Heart Failure (2014-2015)</li> <li>- Vifor International : Heart Failure (2014-2015)</li> <li>- Bayer AG : Heart Failure (2014-2015)</li> <li>- Sphingotec : Biomarkers in Heart Failure (2015)</li> <li>- Novartis : Heart Failure grant and RELAX-AHF (2015)</li> </ul>

## 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Abdel-Massih Tony	Nothing to be declared (2014-2015)
Abir-Khalil Saadia	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Novartis : cardiology (2014-2015) - Pfizer : cardiology (2014-2015) - Sanofi Aventis : cardiology (2014-2015)
Aboyans Victor	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : Antithrombotics (2014) - Sanofi Aventis : Hyperlipidemia (2014-2015) - Novartis : Hypertension (2014-2015) - Boehringer-Ingelheim : Oral anticoagulation (2014-2015) - Bayer Healthcare : Oral anticoagulation (2014-2015) - Pfizer/BMS alliance : Oral anticoagulation (2014-2015)
Achenbach Stephan	Nothing to be declared (2015) D - Research funding (departmental or institutional). - Abbott : Coronary Intervention (2014)
Agathangelou Petros	Nothing to be declared (2014-2015)
Agewall Stefan	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Thermo Fischer Scientific : Cardiac markers (2014-2015) - Astra Zeneca : Platelet inhibition (2014-2015) - Vifor International : Heart failure (2015)
Aidargaliyeva Nazipa	Nothing to be declared (2014-2015)
Aladashvili Alexander	Nothing to be declared (2014-2015)
Al-Attar Nawwar	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Johnson & Johnson : haemostasis (2014-2015)
Atherton John James	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astrazeneca : Acute coronary syndromes, heart failure (2014)

## 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Atherton John James	<ul style="list-style-type: none"> <li>- Genzyme : Enzyme replacement therapy (2014)</li> <li>- Novartis : Heart failure (2014-2015)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer : Heart failure: BAY 94-8862 (2014)</li> <li>- Novartis : Heart failure: Serelaxin (2014-2015)</li> <li>- Servier : Heart failure: Ivabradine (2015)</li> <li>- Bayer : Heart failure: vericiguat, finerenone (2015)</li> </ul>
Bajraktari Gani	Nothing to be declared (2014-2015)
Bauersachs Johann	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Lilly : ACS (2014)</li> <li>- Astra Zeneca : ACS (2014-2015)</li> <li>- Daiichi Sankyo : ACS (2014-2015)</li> <li>- Boehringer-Ingelheim : Afib (2014-2015)</li> <li>- Bristol Myers Squibb : Afib (2014-2015)</li> <li>- Bayer : Afib, heart failure (2014-2015)</li> <li>- Merck Sharp &amp; Dohme : CAD, Afib (2014-2015)</li> <li>- Pfizer : Heart Failure, Afib (2014-2015)</li> <li>- Medtronic : Heart Failure, Hypertension (2014-2015)</li> <li>- Berlin Chemie AG : Hypertension, CAD (2014-2015)</li> <li>- Novartis : Hypertension, Heart Failure (2014-2015)</li> <li>- Servier : Heart Failure (2015)</li> <li>- Thoratec : Heart Failure (2015)</li> <li>- Heartware : Heart Failure (2015)</li> </ul>

## 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Bauersachs Johann	<ul style="list-style-type: none"> <li>- Biotronik : Heart Failure, CAD (2015)</li> <li>D - Research funding (departmental or institutional).</li> <li>- Sanofi Aventis : Heart Failure (2014)</li> <li>- Medtronic : CAD (2014-2015)</li> <li>- Actavis : Heart Failure, CAD (2014-2015)</li> <li>- Bayer : Vascular remodeling (2014-2015)</li> </ul>
Beishenkulov Medet	Nothing to be declared (2014-2015)
Camm John	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- ChanRx : antiarrhythmic drug (2014)</li> <li>- Boehringer-Ingelheim : Dabigatran (2014)</li> <li>- Bristol Myers Squibb : DSMB (2014)</li> <li>- Novartis : DSMB - several (2014)</li> <li>- Johnson &amp; Johnson : Apixaban (2014-2015)</li> <li>- Wiley Blackwell : Clinical Cardiology (2014-2015)</li> <li>- Biotronik : DSMB - Ablation (2014-2015)</li> <li>- Infobionics : ECG monitoring (2014-2015)</li> <li>- Oxford University Press : Europace and ESC textbook (2014-2015)</li> <li>- GlaxoSmithKline : General Advice (2014-2015)</li> <li>- Servier : Multiple products (2014-2015)</li> <li>- Sanofi Aventis : Multiple products (2014-2015)</li> <li>- Menarini : Ranolazine (2014-2015)</li> <li>- Gilead : Ranolazine (2014-2015)</li> <li>- Bayer : Rivaroxaban (2014-2015)</li> </ul>



## 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Camm John	<ul style="list-style-type: none"> <li>- Medtronic : Subcutaneous monitoring (2014-2015)</li> <li>- Bristol Myers Squibb : Apixaban (2015)</li> <li>- Sorin Group : Atrial fibrillation (2015)</li> <li>- Eli Lilly : Cardiovascular safety of oncology product (2015)</li> <li>- NeRRe Pharma : CV safety of neurology product (2015)</li> <li>- Boehringer-Ingelheim : Dabigatran and Idarucizumab (2015)</li> <li>- Boston Scientific : General advice (2015)</li> <li>- InCarda : Inhaled flecainide (2015)</li> <li>- Milestone : New calcium channel blocker (2015)</li> <li>- ChanRx/Laguna : Vanoxerine antiarrhythmic drug (2015)</li> <li>D - Research funding (departmental or institutional).               <ul style="list-style-type: none"> <li>- Servier : Antiarrhythmic drug (2014-2015)</li> <li>- BMS/Pfizer : Apixaban (2014-2015)</li> <li>- Daiichi Sankyo : Edoxaban (2014-2015)</li> <li>- Richmond Pharmacology : Many phase 1 NCEs (2014-2015)</li> <li>- Thrombosis Research Institute : Anticoagulation for atrial fibrillation (2015)</li> <li>- Boehringer Ingelheim : Atrial fibrillation registry (2015)</li> </ul> </li> </ul>
Carerj Scipione	Nothing to be declared (2014-2015)
Cassar Andrew	Nothing to be declared (2014-2015)
Ceconi Claudio	Nothing to be declared (2014-2015)
Celutkienė Jelena	<ul style="list-style-type: none"> <li>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.               <ul style="list-style-type: none"> <li>- Bayer : Finerenone (2014)</li> <li>- Berlin Chemie AG : Nebivolol (2014)</li> </ul> </li> </ul>

## 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Celutkiene Jelena	<ul style="list-style-type: none"> <li>- Amgen Inc : Omecamtiv (2014)</li> <li>- Servier : Ivabradin (2014-2015)</li> <li>- Roche Diagnostics : NT-proBNP (2015)</li> <li>- Amgen : Omecamtiv (2015)</li> <li>- Johnson &amp; Johnson : Rivaroxaban (2015)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - NIH : Stable Ischemic heart disease (2014-2015)</p> <p>D - Research funding (departmental or institutional). - Lithuanian Research Council : Metabolic syndrome (2014)</p> <p>E - Research funding (personal). - Lithuanian Research Council : Acute heart failure (2015)</p>
Chioncel Ovidiu	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : Heart Failure: Advisory Board (2014) - Philips : Imaging-Speaker fees (2014)</p> <p>- Novartis : Heart Failure: Steering Committee, Advisory Board (2014-2015) - Servier : Heart Failure: Steering Committee, Advisory Board (2015)</p> <p>D - Research funding (departmental or institutional). - Vifor International : Anemia FERIC RO registry (2014) - Novartis : Heart Failure-FERIC RO registry (2014)</p>
Chrysohoou Christina	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Merck Sharp &amp; Dohme : hypolipidemic therapy (study Improve It) advisory board fees (2014) - Novartis : Heart Failure (2015)</p> <p>- MSD : Lipid Therapy (2015) - Amgen : PCSK9 study (2015) - Sanofi Aventis : PCSK9 study (2015)</p>

## 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Chrysohoou Christina	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.            - Servier : investigator for ivabradine (2014)            - MSD : Honoraria (2015)</p> <p>D - Research funding (departmental or institutional).            - Servier : Research finding in Heart Failure (2015)</p>
Coca Antonio	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.            - Daiichi Sankyo : Olmesartan; Olmesartan-Amlodipine; Olmesartan-HCTZ; triple combinations (2014)            - Novartis : Valsartan-Amlodipine; triple combinations; Serelaxin (2014)            - Recordati International : Azilsartan; Lercanidipine; combos (2014-2015)            - Menarini : Nebivolol; Olmesartan; Olmesartan-Amlodipine; Olmesartan-HCTZ (2014-2015)            - Servier : Perindopril; indapamide; combos; triple combinations (2014-2015)            - Ferrer Internacional : Torasemide; CardiIncode microchips; Polypill (2014-2015)</p>
Davies Ceri	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.            - Servier : Heart Failure (2014-2015)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.            - Amgen Inc : Heart Failure (2014)</p> <p>D - Research funding (departmental or institutional).            - Amgen Inc : Heart failure (2015)</p>
Di Lenarda Andrea	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.            - Daiichi Sankyo : Anticoagulants (2014)            - Astra Zeneca : Cardiovascular Prevention (2014)            - Merck Sharp &amp; Dohme : Cardiovascular Prevention (2014)            - Sigma Tau : Cardiovascular Prevention (2014)            - Recordati International : Cardiovascular Prevention (2014)            - Takeda Pharmaceuticals : Diabetes and Heart Failure (2014)            - Servier : Heart Failure (2014)</p>

## 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Di Lenarda Andrea	<ul style="list-style-type: none"> <li>- Malesci : Hypertension (2014)</li> <li>- Menarini : Ischemic heart Disease (2014)</li> <li>- Novartis : Heart Failure (2014-2015)</li> </ul>
Diaz Molina Beatriz	<p>Nothing to be declared (2014)</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Novartis : TRANSPLANT (2015)</li> <li>- Astellas : TRANSPLANT (2015)</li> </ul>
Elliott Perry Mark	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Shire HGT : Enzyme replacement therapy Fabry disease (2014-2015)</li> <li>- Genzyme : Enzyme replacement therapy Fabry disease (2014-2015)</li> <li>- MyoKardia : Mutation guided therapies in cardiomyopathy (2014-2015)</li> <li>- Pfizer : Treatment for TTR amyloidosis (2014-2015)</li> <li>- Amicus : Chaperone therapy for Fabry Disease (2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Genzyme : Cardiac magnetic resonance imaging in HCM (2014-2015)</li> <li>- Shire HGT : Clinical characterisation of Anderson-Fabry Disease (2014-2015)</li> <li>- National Institute for Health and Clinical Excellence : Genetics of hypertrophic cardiomyopathy (2014-2015)</li> <li>- British Heart Foundation : Hypertrophic cardiomyopathy (2014-2015)</li> </ul>
Erol Cetin	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Servier : Hypertension (2014-2015)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Menarini : Hypertension (2014-2015)</li> </ul>
Ezekowitz Justin	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bristol Myers Squibb : Atrial fibrillation (2014-2015)</li> <li>- Amgen : heart failure (2014-2015)</li> <li>- Bayer : Heart failure (2014-2015)</li> </ul>

## 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Ezekowitz Justin	<ul style="list-style-type: none"> <li>- Novartis : heart failure (2014-2015)</li> <li>- Servier : heart failure (2014-2015)</li> </ul>
Fernandez-Golfin Covadonga	Nothing to be declared (2014-2015)
Filippatos Gerasimos	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer : Heart failure (2014-2015)</li> <li>- Servier : Heart failure (2014-2015)</li> <li>- Cardiorentis : Heart failure (2014-2015)</li> <li>- Corthera, Novartis : Heart failure (2014-2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Alere : Biomarkers (2014)</li> </ul> <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> <li>- European Union : Heart failure (2014-2015)</li> </ul>
Fitzsimons Donna	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Amgen : FH Treatment options (2014)</li> <li>- Amgen : lipid management (2015)</li> </ul>
Fonseca Candida	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Servier : Heart Failure Trials (EDIFY, QUALIFY) Nacional Coordinator/Steering Committees member (2014)</li> <li>- Orion : Levosimendan Advisory Board membre and Speaker (2014-2015)</li> <li>- Bayer : Novel Oral Anticoagulants / Speaker and Rivaroxaban Nacional Advisory Board membre (2014-2015)</li> <li>- Novartis : Steering Committee of ATMOSPHERE, and EU-RELAX Studies/National coordinator and Relaxin advisory Board membre (2014-2015)</li> <li>- Servier : Heart Failure Trials ( QUALIFY) Nacional Coordinator/Steering Committees member (2015)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- OmPharma : Grant for investigation in anemia and iron deficiency area (2014)</li> <li>- Bayer : mineralocorticoide antagonist in Heart failure (2014)</li> <li>- Novartis : Heart failure Trials (2014-2015)</li> </ul>

## 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Fonseca Candida	<ul style="list-style-type: none"> <li>- Servier : Investigation/Heart Failure Trials (2014-2015)</li> <li>- Orion : levosimendan. Acute heart failure (2015)</li> <li>- Bayer : mineralocorticoide antagonist in Heart failure and Rivaroxaban (2015)</li> </ul>
Goncalvesova Eva	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Novartis : heart failure (2014-2015)</li> <li>- Actelion : pulmonary hypertension (2014-2015)</li> <li>- AOP Orphan Pharmaceuticals : pulmonary hypertension (2014-2015)</li> <li>- Servier : heart failure (2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Novartis : heart failure (2014)</li> </ul>
Guazzi Marco	Nothing to be declared (2014-2015)
Guenoun Maxime	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : cardiology (2014-2015)</li> <li>- Boehringer-Ingelheim : cardiology (2014-2015)</li> <li>- Pfizer : cardiology (2014-2015)</li> <li>- Servier : cardiology (2014-2015)</li> <li>- Meda pharma : cardiology (2014-2015)</li> <li>- Bayer Healthcare : cardiology (2014-2015)</li> <li>- Bristol Myers Squibb : cardiology (2014-2015)</li> <li>- Medtronic : pacing (2014-2015)</li> <li>- Sorin Group : pacing (2014-2015)</li> </ul>
Hasenfuss Gerd	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- DC Devices : REDUC ELAP device trial (2014)</li> <li>- Astrazeneca : Therapeutic (2014)</li> </ul>

## 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Hasenfuss Gerd	<ul style="list-style-type: none"> <li>- Bayer : Xarelta (2014)</li> <li>- Circulite : Assist device (2014-2015)</li> <li>- Servier : Ivabradine, RYCALs (2014-2015)</li> <li>- Impulse Dynamics : Optimizer (2014-2015)</li> <li>- Novartis : Serelaxine (2014-2015)</li> <li>- CVRx : Baroreceptor Stimulation (2015)</li> <li>- Astrazeneca : Hesrt failure (2015)</li> <li>- Corvia Medical : REDUC ELAP device trial (2015)</li> <li>- Bayer : Xarelto. Heart Failure (2015)</li> </ul>
Hassanein Mahmoud	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Novartis : cardiology (2014-2015)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Amgen : cardiology (2014-2015)</li> <li>- Astra Zeneca : cardiology (2014-2015)</li> <li>- Pfizer : cardiology (2014-2015)</li> <li>- Servier : cardiology (2014-2015)</li> <li>- Sanofi Aventis : cardiology (2014-2015)</li> <li>- Merck Sharp &amp; Dohme : cardiology (2014-2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Servier : Euro-observational Research Program- Heart Failure-long term registry (2014-2015)</li> </ul>
Hindricks Gerhard	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Biotronik : ICD, CRT (2014)</li> <li>- Boston Scientific : IC, CRT, Catheter Ablation (2014-2015)</li> <li>- St Jude Medical : ICD, CRT, Catheter Ablation (2014-2015)</li> </ul>

## 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Hindricks Gerhard	<ul style="list-style-type: none"> <li>- Biotronik : ICD CRT (2015)</li> <li>D - Research funding (departmental or institutional).               <ul style="list-style-type: none"> <li>- Daiichi Sankyo : atrial fibrillation, anticoagulation (2014-2015)</li> <li>- Boston Scientific : ICD, CRT, Catheter Ablation (2014-2015)</li> <li>- St Jude Medical : ICD, CRT, Catheter Ablation (2014-2015)</li> <li>- Biotronik : ICD, CRT, Catheter Ablation (2014-2015)</li> <li>- Zoll Medical : wearable ICD (2014-2015)</li> </ul> </li> </ul>
Hoes Arno	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Various : I chair a large (around 500 employees) research and teaching institute within our University Medical Center. We perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. In addition, some of my members of staff receive unrestricted grants for research projects from a number of companies. It is our explicit policy to work with several companies and not to focus on one or two industrial partners. I receive no personal payment from any industrial partner. (2014)</li> <li>- Zorg binnen Bereik : Member of project team of Zorg Binnen Bereik, a Dutch Achmea (health insurance company) and Philips sponsored research program to test patient e-health platforms in patients with chronic disease (heart failure, COPD and diabetes) (2014)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- I am the director of a large (around 500 employees) research and teaching institute within our University Medical Center. We perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. In addition, some of my members of staff receive unrestricted grants for research projects from a number of companies. It is our explicit policy to work with several companies and not to focus on one or two industrial partners. I receive no personal payment from any industrial partner. (2014)</li> <li>- I am the director of a large (around 500 employees) research and teaching institute within our University Medical Center. We perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. : I chair a large (around 500 employees) research and teaching institute within our University Medical Center. We perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. In addition, some of my members of staff receive unrestricted grants for research projects from a number of companies. It is our explicit policy to work with several companies and not to focus on one or two industrial partners. I receive no personal payment from any industrial partner. (2015)</li> </ul>
Isayev Elnur	Nothing to be declared (2014-2015)



## 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
lung Bernard	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Abbott : Mitraclip (2014) - Boehringer-Ingelheim : dabigatran (2014-2015) - Edwards Lifesciences : heart valve prosthesis (2014-2015)
Jaarsma Tiny	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Amgen : Evolocumab (2014) - Biotronik : no special product (2014) - Novartis : no special product (2015)  B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Novartis : no special product (2015)
Juilliere Yves	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - GlaxoSmithKline : Anti-diabetic drugs (2014) - Alere : BNP (2014) - Novartis : Heart Failure (2014) - Boston Scientific : Heart Failure e-health (2014) - St Jude Medical : Heart Failure e-health (2014) - Amgen : Hypercholesterolemia (2014) - Merck Sharp & Dohme : Hypocholesterolemia (2014) - Abbott Vascular : Mitraclip (2014) - Pfizer : New Anticoagulants (2014) - Bristol Myers Squibb : New anticoagulants (2014) - Medicines Company : SCA (2014) - Medicines Company : Antiagregant therapy (2015) - Bayer : Anticoagulant therapy (2015)

## 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Juilliere Yves	<ul style="list-style-type: none"> <li>- Pfizer : Anticoagulant therapy (2015)</li> <li>- Amgen : Anti-PCSK9 (2015)</li> <li>- Sanofi Aventis : Anti-PCSK9 (2015)</li> <li>- Abbott Vascular : BVS (2015)</li> <li>- GlaxoSmithKline : Cardiology (2015)</li> <li>- Merck Sharp &amp; Dohme : Dyslipidemia (2015)</li> <li>- Astra Zeneca : Heart failure and dyslipidemia (2015)</li> <li>- St Jude Medical : Heart failure devices (2015)</li> <li>- Novartis : Heart failure therapy (2015)</li> <li>- Servier : Heart failure therapy (2015)</li> <li>- Roche Diagnostics : Natruretic peptides (2015)</li> <li>- Boston Scientific : Percutaneous coronary interventions (2015)</li> </ul>
Kamzola Ginta	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Grindeks : Cardiology; Consultancy (2014)</li> <li>- Novartis Pharma Serv. AG : Echocardiography in terms of clinical trial; Speaker fee; Advisory Board fee (2014)</li> <li>- Diamedica SIA : Heart failure. Honoraria (2014)</li> <li>- Berlin Chemie Menarini : Heart failure. Speaker fee (2014)</li> <li>- Servier : Heart failure, Speaker fee (2014-2015)</li> <li>- Bayer : Prevention of systemic embolism and stroke in AFib . Speaker fee (2014-2015)</li> <li>- Berlin Chemie AG : Heart failure, Speaker fee (2015)</li> <li>- Sandoz : Heart failure, Speaker fee (2015)</li> <li>- Merck Serono : Heart failure, Speaker fee (2015)</li> <li>- Novartis : Heart failure, Speaker fee; Advisory Board fee (2015)</li> </ul>

## 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Kamzola Ginta	- Boehringer-Ingelheim : Prevention of systemic embolism and stroke in AFib . Speaker fee (2015)
Kirchhof Paulus	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Daiichi Sankyo : cardiovascular (2014)</li> <li>- Pfizer : cardiovascular (2014)</li> <li>- Bristol Myers Squibb : cardiovascular (2014)</li> <li>- Boehringer-Ingelheim : cardiovascular (2014-2015)</li> <li>- Medtronic : cardiovascular (2014-2015)</li> <li>- St Jude Medical : cardiovascular (2014-2015)</li> <li>- Sanofi Aventis : cardiovascular (2014-2015)</li> <li>- Meda pharma : cardiovascular (2014-2015)</li> <li>- Merck Sharp &amp; Dohme : cardiovascular (2014-2015)</li> <li>- Medscape : cardiovascular (2014-2015)</li> <li>- Astra Zeneca : cardiovascular (2015)</li> <li>- Servier : cardiovascular (2015)</li> <li>- Bayer Healthcare : cardiovascular (2015)</li> <li>- Bayer Vital : cardiovascular (2015)</li> <li>- Correvio : cardiovascular (2015)</li> <li>- Daiichi Sankyo Europe : cardiovascular (2015)</li> <li>- Bristol Myers Squibb Global : cardiovascular (2015)</li> <li>- Pfizer Global : cardiovascular (2015)</li> <li>- Pfizer Germany : cardiovascular (2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Daiichi Sankyo : cardiovascular (2014-2015)</li> </ul>

## 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Kirchhof Paulus	<ul style="list-style-type: none"> <li>- St Jude Medical : cardiovascular (2014-2015)</li> <li>- Sanofi Aventis : cardiovascular (2014-2015)</li> <li>- Meda pharma : cardiovascular (2014-2015)</li> <li>- British Heart Foundation : cardiovascular (2014-2015)</li> <li>- BMS / Pfizer alliance : cardiovascular (2014-2015)</li> <li>- Leducq Foundation : cardiovascular (2014-2015)</li> <li>- European Union FP7 : cardiovascular (2014-2015)</li> <li>- European Union horizon2020 : cardiovascular (2014-2015)</li> <li>- German Centre for Heart Research (DZHK, funded by German Ministry of Education and Research) : cardiovascular (2014-2015)</li> <li>- UK Medical Research Council : cardiovascular (2015)</li> </ul>
Knuuti Juhani	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- GE Healthcare : Imaging (speakers fee) (2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Servier : Vascular inflammation (2014)</li> <li>- Athera : vascular inflammation (2014)</li> <li>- CardiRad : Regadenoson (2015)</li> </ul>
Kolh Philippe H	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Antiplatelet agents (2014-2015)</li> <li>- B.Braun : Surgical instruments (2014-2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Edwards Lifesciences : Cardiac valves (2014-2015)</li> <li>- Medtronic : Cardiac valves (2014-2015)</li> </ul>
Konstantinides Stavros V	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Antiplatelet agents (2014)</li> <li>- Boehringer-Ingelheim : Anticoagulation (2014-2015)</li> </ul>

## 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Konstantinides Stavros V	<ul style="list-style-type: none"> <li>- Daiichi Sankyo : Anticoagulation (2014-2015)</li> <li>- Bristol Myers Squibb : Anticoagulation (2014-2015)</li> <li>- Bayer Healthcare : Anticoagulation; pulmonary hypertension (2014-2015)</li> <li>D - Research funding (departmental or institutional).               <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : Anticoagulation (investigator initiated trials) (2014-2015)</li> <li>- Bayer Healthcare : Anticoagulation (investigator initiated trials) (2014-2015)</li> </ul> </li> </ul>
Kurlianskaya Alena	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Takeda Pharmaceuticals : Heart Failure (speaker) (2014-2015)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Servier : QUALIFY (investigator) (2014-2015)</li> </ul>
Lainscak Mitja	<p>Nothing to be declared (2014)</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Novartis : Heart failure (2015)</li> <li>- Servier : heart failure (2015)</li> <li>- Relypsa : heart failure (2015)</li> </ul>
Lancellotti Patrizio	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Menarini : nebivolol (2014)</li> <li>- St Jude Medical : Echo course (2015)</li> <li>- Servier : Imaging Ischemic disease (2015)</li> <li>- Boston Scientific : Sudden death (2015)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Boston Scientific : CRT (2014)</li> <li>- Servier : procoralan (2014)</li> <li>- Bayer : NOAC (2015)</li> </ul>
Lip Gregory Y H	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Medtronic : atrial fibrillation (2014-2015)</li> </ul>

## 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Lip Gregory Y H	<ul style="list-style-type: none"> <li>- Biotronik : atrial fibrillation (2014-2015)</li> <li>- Boehringer-Ingelheim : atrial fibrillation, thrombosis (2014-2015)</li> <li>- Daiichi Sankyo : atrial fibrillation, thrombosis (2014-2015)</li> <li>- Pfizer : atrial fibrillation, thrombosis (2014-2015)</li> <li>- Bayer Healthcare : atrial fibrillation, thrombosis (2014-2015)</li> <li>- Bristol Myers Squibb : atrial fibrillation, thrombosis (2014-2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Daiichi Sankyo : atrial fibrillation, thrombosis (2014-2015)</li> </ul>
Lommi Jyri Jukka	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Servier : speakers fee (2014)</li> <li>- Novartis : drugs (2015)</li> <li>- Orion : drugs (2015)</li> <li>- Servier : drugs (2015)</li> </ul>
Luchner Andreas	Nothing to be declared (2014-2015)
Maisano Francesco	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Abbott Vascular : mitraclip (2014-2015)</li> <li>- Medtronic : tavi (2014-2015)</li> <li>- St Jude Medical : tavi (2014-2015)</li> <li>- Directflow medical : Tavi (2014-2015)</li> <li>- Valtechcardio : transcatheter mitral therapies (2014-2015)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Abbott Vascular : Mitraclip (2014-2015)</li> </ul> <p>C - Receipt of royalties for intellectual property.</p> <ul style="list-style-type: none"> <li>- Edwards Lifesciences : mitral repair (2014-2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Abbott Vascular : Mitraclip (2014-2015)</li> </ul>

## 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
McMurray John	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Novartis : Various speaking engagements (2014)</li> <li>- GSK : albiglutide/prolyl hydroxylase inhibitor (Trial endpoint committee/executive committees) (2015)</li> <li>- Novartis : aliskiren (Trial executive committee) (2015)</li> <li>- Theracos : Bexagliflozin (Trial executive committee) (2015)</li> <li>- Amgen Inc : omecamtiv mecarbil (Trial steering committee) (2015)</li> <li>- Novartis : sacubitril/valsartan (Trial executive committee, advisory boards, lectures) (2015)</li> <li>- Cardioentis : ularitide (Trial executive committee/to run endpoint committee) (2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Oxford University : ACE study (Steering Committee) - My employer, the University of Glasgow is paid by the study sponsor for my time working on this trial. The study sponsor pays for my travel/accommodation related to trial committee/investigator meetings. (2014)</li> <li>- Novartis : ATMOSPHERE (Co-chair of Steering Committee) - My employer, the University of Glasgow is paid by the study sponsor for my time working on this trial. The study sponsor pays for my travel/accommodation related to trial committee/investigator meetings. (2014)</li> <li>- Amgen : COSMIC-HF (Executive Committee) - My employer, the University of Glasgow is paid by the study sponsor for my time working on this trial. The study sponsor pays for my travel/accommodation related to trial committee/investigator meetings. (2014)</li> <li>- Sanofi-Aventis : ELIXA study (Executive Committee) - My employer, the University of Glasgow is paid by the study sponsor for my time working on this trial. The study sponsor pays for my travel/accommodation related to trial committee/investigator meetings. (2014)</li> <li>- University of Dundee : FAST study (Steering Committee) - My employer, the University of Glasgow is paid by the study sponsor for my time working on this trial. The study sponsor pays for my travel/accommodation related to trial committee/investigator meetings. (2014)</li> <li>- GlaxoSmithKline : Harmony Outcomes study (Co-chair Steering Committee) - My employer, the University of Glasgow is paid by the study sponsor for my time working on this trial. The study sponsor pays for my travel/accommodation related to trial committee/investigator meetings. (2014)</li> <li>- Merck Sharp &amp; Dohme : MK-3102 (DSMB) - My employer, the University of Glasgow is paid by the study sponsor for my time working on this trial. The study sponsor pays for my travel/accommodation related to trial committee/investigator meetings. (2014)</li> </ul>

## 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
McMurray John	<ul style="list-style-type: none"> <li>- Novartis : PARADIGM study Co-chair Steering Committee) - My employer, the University of Glasgow is paid by the study sponsor for my time working on this trial. The study sponsor pays for my travel/accommodation related to trial committee/investigator meetings. (2014)</li> <li>- Novartis : PARAGON study - My employer, the University of Glasgow is paid by the study sponsor for my time working on this trial. The study sponsor pays for my travel/accommodation related to trial committee/investigator meetings. (2014)</li> <li>- Kidney Research UK : PIVOTAL study (Steering Committee) - My employer, the University of Glasgow is paid by the study sponsor for my time working on this trial. The study sponsor pays for my travel/accommodation related to trial committee/investigator meetings. (2014)</li> <li>- GlaxoSmithKline : Prolyl hydroxylase study (Executive Committee) My employer, the University of Glasgow is paid by the study sponsor for my time working on this trial. The study sponsor pays for my travel/accommodation related to trial committee/investigator meetings. (2014)</li> <li>- Dundee University : SCOT study (Endpoint Committee) - My employer, the University of Glasgow is paid by the study sponsor for my time working on this trial. The study sponsor pays for my travel/accommodation related to trial committee/investigator meetings. (2014)</li> <li>- Dundee University : SCOT study (Steering Committee) - My employer, the University of Glasgow is paid by the study sponsor for my time working on this trial. The study sponsor pays for my travel/accommodation related to trial committee/investigator meetings. (2014)</li> <li>- Bayer : SOCRATES study (DSMB) - My employer, the University of Glasgow is paid by the study sponsor for my time working on this trial. The study sponsor pays for my travel/accommodation related to trial committee/investigator meetings. (2014)</li> <li>- AbbVie : SONAR study (Steering Committee) - My employer, the University of Glasgow is paid by the study sponsor for my time working on this trial. The study sponsor pays for my travel/accommodation related to trial committee/investigator meetings. (2014)</li> <li>- Pfizer : SPIRE study (DSMB) - My employer, the University of Glasgow is paid by the study sponsor for my time working on this trial. The study sponsor pays for my travel/accommodation related to trial committee/investigator meetings. (2014)</li> <li>- Oxford/Duke University : TECOS study (DSMB) - My employer, the University of Glasgow is paid by the study sponsor for my time working on this trial. The study sponsor pays for my travel/accommodation related to trial committee/investigator meetings. (2014)</li> <li>- Cardioentis : TRUE-AHF (Endpoint Committee) - My employer, the University of Glasgow is paid by the study sponsor for my time working on this trial. The study sponsor pays for my travel/accommodation related to trial committee/investigator meetings. (2014)</li> <li>- Cardioentis : TRUE-AHF (Executive Committee) - My employer, the University of Glasgow is paid by the study sponsor for my time working on this trial. The study sponsor pays for my travel/accommodation related to trial committee/investigator meetings. (2014)</li> </ul>



## 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
McMurray John	<ul style="list-style-type: none"> <li>- NIHR : UK-TAVI study - My employer, the University of Glasgow is paid by the study sponsor for my time working on this trial. The study sponsor pays for my travel/accommodation related to trial committee/investigator meetings. (2014)</li> <li>- NIH : VANISH study (Steering Committee) - My employer, the University of Glasgow is paid by the study sponsor for my time working on this trial. The study sponsor pays for my travel/accommodation related to trial committee/investigator meetings. (2014)</li> </ul>
Melenovsky Vojtech	Nothing to be declared (2014-2015)
Mo Rune	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Novartis : LCZ696 (2014)</li> <li>- Vifor International : Ferinject (2014-2015)</li> <li>- Novartis : Entresto (2015)</li> </ul>
Mueller Christian Eugen	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Novartis : Acute Heart Failure (2014-2015)</li> <li>- Cardiorentis : Acute Heart Failure (2014-2015)</li> <li>- Bristol Myers Squibb : Anticoagulation (2014-2015)</li> <li>- Astra Zeneca : Antiplatelet therapy (2014-2015)</li> <li>- Daiichi Sankyo : Antiplatelet therapy (2014-2015)</li> <li>- Lilly : Antiplatelet therapy (2014-2015)</li> <li>- BRAHMS GmbH : Diagnostics (2014-2015)</li> <li>- Singulex : Diagnostics (2014-2015)</li> <li>- Abbott Laboratories : Diagnostics (2014-2015)</li> <li>- BG medicine : Diagnostics (2014-2015)</li> <li>- Roche Diagnostics : Diagnostics (2014-2015)</li> <li>- BioMérieux S.A : Diagnostics (2014-2015)</li> <li>- Siemens : Diagnostics (2014-2015)</li> <li>- Sanofi Aventis : Lipids (2014-2015)</li> </ul>

## 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Mueller Christian Eugen	D - Research funding (departmental or institutional). <ul style="list-style-type: none"> <li>- BRAHMS GmbH : Diagnostics (2014-2015)</li> <li>- Singulex : Diagnostics (2014-2015)</li> <li>- Abbott Laboratories : Diagnostics (2014-2015)</li> <li>- Roche Diagnostics : Diagnostics (2014-2015)</li> <li>- BioMérieux S.A : Diagnostics (2014-2015)</li> <li>- Siemens : Diagnostics (2014-2015)</li> <li>- Sphingotec : Diagnostics (2014-2015)</li> <li>- Astra Zeneca : Perioperative care (2014-2015)</li> </ul>
Mullens Wilfried	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none"> <li>- Biotronik, Medtronic : Speakers fee, advisory board (2014-2015)</li> </ul>
Noppe Stephanie	Nothing to be declared (2014-2015)
Nyolczas Noemi	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none"> <li>- Egis Pharma : speaker fees (2014)</li> <li>- Servier : speaker fees, advisory board fees, investigator (2014)</li> <li>- Roche Diagnostics : speaker fees, advisory board fees (2014-2015)</li> <li>- Novartis : speaker fees, advisory board fees, investigator (2014-2015)</li> <li>- Celyad SA : investigator (2015)</li> <li>- Takeda Pharmaceuticals : speaker fees (2015)</li> <li>- Fresenius Medical Care : speaker fees (2015)</li> <li>- Servier : speaker fees, investigator (2015)</li> </ul>
Otasevic Petar	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none"> <li>- Novartis : chronic heart failure (2014-2015)</li> </ul>
Petrie Mark	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none"> <li>- Astra Zeneca : ticagrelor (2014)</li> </ul>

## 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Petrie Mark	<ul style="list-style-type: none"> <li>- Bayer : Acarbose (2014-2015)</li> <li>- Cardioentis : Acute heart failure (2014-2015)</li> <li>- Boehringer-Ingelheim : Diabetes (2014-2015)</li> <li>- GlaxoSmithKline : diabetes (2014-2015)</li> <li>- Maquet : IABPs (2014-2015)</li> <li>- Servier : ivabradine (2014-2015)</li> <li>- Novartis : LCZ696 (2014-2015)</li> <li>- Pfizer : NSAIDs (2014-2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Servier : ivabradine (2014-2015)</li> <li>- Boehringer-Ingelheim : empagliflozin (2015)</li> </ul> <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> <li>- Servier : ivabradine (2015)</li> </ul>
Piepoli Massimo Francesco	<p>Nothing to be declared (2014)</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Servier : Cardiovascular Prevention and Rehabilitation Initiatives (2015)</li> <li>- Novartis : Heart Failure Prevention Initiatives (2015)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Novartis : Heart Failure Prevention Initiatives (2015)</li> </ul>
Priori Silvia Giuliana	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Medtronic : Cardiac Rhythm Management (2014-2015)</li> <li>- Gilead Inc : antiarrhythmic drugs (2015)</li> <li>- Audentes Therapeutics Inc : Gene Therapy (2015)</li> <li>- Cardiogen : Genetics (2015)</li> <li>- GE Healthcare : Health products (2015)</li> </ul>

## 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Priori Silvia Giuliana	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boston Scientific : Cardiac Rhythm Management (2014-2015)</p> <p>D - Research funding (departmental or institutional). - Gilead : antiarrhythmic drugs (2014-2015) - Boston Scientific : epidemiology of Brugada Syndrome (2014-2015)</p>
Schaufelberger Maria	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Novartis : speaker fee (2014) - Novartis : Consultancy (2015)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Pfizer : Investigator (2014-2015) - Bayer AG : Investigator (2014-2015)</p>
Shlyakhto Evgeny	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : Ivabradin (2014) - Krka Pharma : Arterial Hypertension (2014-2015) - Novartis : Arterial Hypertension, Heart Failure (2014-2015) - Merck Sharp &amp; Dohme : Atherosclerosis (2014-2015) - Boehringer-Ingelheim : Dabigatran for Atrial Fibrillation (2014-2015) - Pfizer : General Cardiology (2014-2015)</p>
Sisakian Hamayak	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : Hypertension (2014) - Servier : Indapamide/Amlodipin (2015) - Bayer : Rivaroxaban (2015)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : Indapamide/Amlodipin (2015)</p> <p>D - Research funding (departmental or institutional). - Yerevan State Medical University : No (2015)</p>

## 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Srbinovska-Kostovska Elizabeta	Nothing to be declared (2014-2015)
Straburzynska-Migaj Ewa	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Servier : heart failure (2014)</li> <li>- Sandoz : torasemidum (2014)</li> <li>- Boehringer-Ingelheim : dabigatran (2014-2015)</li> <li>- GE Healthcare : exercise testing (2014-2015)</li> <li>- Polpharma : heart failure (2014-2015)</li> <li>- Berlin Menarini : heart failure (2014-2015)</li> <li>- Bayer Healthcare : heart failure (2015)</li> <li>- Sandoz : heart failure (2015)</li> <li>- Servier : ivabradine (2015)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer Healthcare : heart failure (2014)</li> </ul>
Suter Thomas	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Teva Pharmaceutical Industries : Cancer Therapeutics (2014)</li> <li>- Novartis : Heart Failure (2014)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Novartis, Amgen : Heart Failure, Cancer (2015)</li> </ul>
Thorgeirsson Gestur	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Amgen : Study: FOURIER; Further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk. (2015)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Amgen : FOURIER study, additional cholesterol reduction on major cardiovascular events (2014)</li> <li>- Novartis : Heart failure, PARADIGM study (2014)</li> </ul>
Tokmakova Mariya	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : ACS, prevention (2014-2015)</li> </ul>

## 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Tokmakova Mariya	<ul style="list-style-type: none"> <li>- Bayer : atrial fibrillation (2014-2015)</li> <li>- Boehringer-Ingelheim : atrial fibrillation (2014-2015)</li> <li>- Pfizer : atrial fibrillation, prevention (2014-2015)</li> <li>- Sanofi Aventis : CAD, prevention (2014-2015)</li> <li>- Servier : Heart failure, CAD, hypertension (2014-2015)</li> <li>- Novartis : hypertension, heart failure (2014-2015)</li> <li>- Berlin Chemie AG : Myocardial infarction, hypertension, heart failure (2014-2015)</li> </ul>
Torbicki Adam	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bristol Myers Squibb : Pulmonary arterial hypertension (2014)</li> <li>- GlaxoSmithKline : pulmonary arterial hypertension - ambrisentan (2014)</li> <li>- Lilly : pulmonary arterial hypertension - ambrisentan (2014)</li> <li>- Actelion : pulmonary arterial hypertension - macitentan, selexipag (2014-2015)</li> <li>- Bayer Healthcare : pulmonary arterial hypertension - iloprost, riociguat, VTE - xarelto (2014-2015)</li> <li>- Teva Pharmaceutical Industries : anti-cancer treatment (2015)</li> <li>- Sanofi Aventis : anticoagulants (2015)</li> <li>- AOP Orphan Pharmaceuticals : pulmonary arterial hypertension (2015)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer Healthcare : Pulmonary hypertension (2014-2015)</li> </ul>
Tsutsui Hiroyuki	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer : Cardiovascular (2014-2015)</li> <li>- Boehringer-Ingelheim : Cardiovascular (2014-2015)</li> <li>- Daiichi Sankyo : Cardiovascular (2014-2015)</li> <li>- Bristol Myers Squibb : Cardiovascular (2014-2015)</li> <li>- MSD : Cardiovascular (2014-2015)</li> </ul>

## 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Tsutsui Hiroyuki	<ul style="list-style-type: none"> <li>- Tanabe-Mitsubishi : Cardiovascular (2014-2015)</li> <li>- Teijin : Cardiovascular (2014-2015)</li> <li>- Pfizer : Cardiovascular (2015)</li> <li>- Takeda Pharmaceuticals : Cardiovascular (2015)</li> <li>- Ono : Cardiovascular (2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Bayer : Cardiovascular (2014-2015)</li> <li>- Boehringer-Ingelheim : Cardiovascular (2014-2015)</li> <li>- Daiichi Sankyo : Cardiovascular (2014-2015)</li> <li>- Takeda Pharmaceuticals : Cardiovascular (2014-2015)</li> <li>- Sanofi Aventis : Cardiovascular (2015)</li> <li>- Tanabe : Cardiovascular (2015)</li> </ul>
Uuetoa Tiina	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Berlin Menarini : speaker fees (2014)</li> <li>- Servier : speaker fees, consultancy (2014)</li> <li>- Novartis : advisory board (2015)</li> <li>- Bayer : speaker fee (2015)</li> <li>- Abbott Laboratories : speaker fee (2015)</li> <li>- Pfizer : speaker fees (2015)</li> <li>- Servier : speaker fees (2015)</li> <li>- Berlin Chemie AG : speaker fees (2015)</li> <li>- Astrazeneca : speaker fees (2015)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer : advisory board fees, speaker fees (2014)</li> </ul>

## 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Uuetoa Tiina	- Astra Zeneca : speaker fees (2014)
Van Pol Petra	Nothing to be declared (2014-2015)
van Veldhuisen Dirk	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Novartis : heart failure (2014-2015) - Cardioentis : heart failure (2014-2015) - Johnson & Johnson : heart failure (2014-2015) - Vifor International : heart failure (2014-2015) - BioControl : Heart failure (2014-2015)  D - Research funding (departmental or institutional). - St Jude Medical : arrhythmias (2014-2015)
Vataman Eleonora	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Egis Pharma : consultancy (2014) - Servier : speaker (2014) - Sanofi Aventis : speaker (2014) - Berlin Chemie AG : speaker (2014) - Promed : speaker (2014) - GEdeon Rihter : Consultancy (2015) - Egis Pharma : scientific collaboration (2015)
Voronkov Leonid	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : Chronic heart failure (2014-2015) - Pfizer : Chronic heart failure (2015)
Weinstein Jean Marc	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Novartis : Consultancy/Advisory board fees for Entresto (2015)  B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Sensible : For participation in multicentre research in heart failure (2014-2015)



## 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Weinstein Jean Marc	D - Research funding (departmental or institutional). - Sensible : For participation in multicentre research in heart failure (2014-2015)
Wiggers Henrik	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Daiichi Sankyo : Atrial fibrillation (2014-2015) - Merck Sharp & Dohme : Atrial fibrillation, hypercholesterolemia (2014-2015) - Bayer Healthcare : Deep vein thrombosis, pulmonary embolism (2014-2015) - Novo-Nordisk : Heart failure and Diabetes (2014-2015) - Pfizer : Hypercholesterolemia (2014-2015) - Servier : Hypercholesterolemia (2014-2015) - Sanofi Aventis : Hypercholesterolemia (2014-2015) - Novartis : Hypercholesterolemia, Heart Failure (2014-2015)
Windecker Stephan	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Eli Lilly : Antiplatelet therapy (2014) - Bayer Healthcare : Antithrombotic drug (2014) - Abbott : Stent and Heartvalvetherapy (2014) - Biosensors : Stents (2014) - Boston Scientific : Stents (2014) - Astra Zeneca : Antiplatelet therapy (2014-2015) - Daiichi Sankyo : Antiplatelet therapy (2015) - Boston Scientific : Complex PCI (2015) - Sanofi Aventis : Managing Dyslipidemia (2015)  D - Research funding (departmental or institutional). - Medicines Company : Antithrombotic therapy (2014) - Johnson & Johnson : Catheters (2014)

## 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Windecker Stephan	<ul style="list-style-type: none"> <li>- Edwards Lifesciences : Heartvalves (2014)</li> <li>- St Jude Medical : OCT (2014)</li> <li>- Abbott : Stent (2014)</li> <li>- Biotronik : Stent (2014)</li> <li>- Boston Scientific : Stent and Heartvalves (2014)</li> <li>- Medtronic : Stent and Heartvalves (2014)</li> <li>- Sorin Group : Electrophysiology (2015)</li> <li>- Biotronik : Electrophysiology (2015)</li> <li>- Johnson &amp; Johnson : Electrophysiology and PCI (2015)</li> <li>- Guerbet : Imaging (2015)</li> <li>- Novartis : IMP (2015)</li> <li>- Actelion : IMP (2015)</li> <li>- Medicines Company : IMP (2015)</li> <li>- Merck Sharp &amp; Dohme : IMP (2015)</li> <li>- St Jude Medical : PCI (2015)</li> <li>- Abbott : PCI and Structural Heart Disease (2015)</li> <li>- Boston Scientific : Structural Heart Disease (2015)</li> <li>- Edwards Lifesciences : Structural Heart Disease (2015)</li> <li>- Symetis SA : Structural Heart Disease (2015)</li> <li>- Medtronic : Structural Heat Disease (2015)</li> </ul>
Yancy Clyde	Nothing to be declared (2014-2015)
Yilmaz Mehmet Birhan	<ul style="list-style-type: none"> <li>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</li> <li>- Novartis : Aliskiren (Investigator) (2014-2015)</li> </ul>

## 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Yilmaz Mehmet Birhan	<ul style="list-style-type: none"> <li>- Novartis : LCZ696 (2014-2015)</li> <li>- Novartis : Serelaxin (2014-2015)</li> <li>- Cardioentis : Ularitide (2014-2015)</li> </ul>
Zamorano Gomez Jose Luis	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Philips : 3D echo (2014)</li> <li>- Toshiba medical imaging : fusion imaging 3D echo CT (2014)</li> <li>- Astra Zeneca : Speaker fee for 1 talk in 2014 (2014)</li> <li>- MSD : CV risk factors (2014-2015)</li> <li>- Abbott : Lecturing (2015)</li> <li>- Pfizer : Lecturing (2015)</li> <li>- Sorin Group : Respicardia echo protocol (2015)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Siemens Healthcare : 3d echo software and free style echo (2014-2015)</li> <li>- Toshiba medical imaging : Fusion Imaging (2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Amgen : Clinical trial (2014-2015)</li> <li>- Novartis : Clinical trial (2014-2015)</li> <li>- Ikaria : Clinical trial (2014-2015)</li> </ul>
Zavatta Marco	Nothing to be declared (2014-2015)

## Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Aboyans Victor	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Antithrombotics (2014)</li> <li>- Sanofi Aventis : Hyperlipidemia (2014-2015)</li> <li>- Novartis : Hypertension (2014-2015)</li> <li>- Boehringer-Ingelheim : Oral anticoagulation (2014-2015)</li> <li>- Bayer Healthcare : Oral anticoagulation (2014-2015)</li> <li>- Pfizer/BMS alliance : Oral anticoagulation (2014-2015)</li> </ul>
Achenbach Stephan	<p>Nothing to be declared (2015)</p> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Abbott : Coronary Intervention (2014)</li> </ul>
Agewall Stefan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Thermo Fischer Scientific : Cardiac markers (2014-2015)</li> <li>- Astra Zeneca : Platelet inhibition (2014-2015)</li> <li>- Vifor International : Heart failure (2015)</li> </ul>
Badimon Lina	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- MSD-España : Lipids (2014)</li> <li>- Sanofi Aventis : lipids (2014-2015)</li> <li>- Burson Masteller : nutrition (2014-2015)</li> <li>- Astra Zeneca : thrombosis (2014-2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Astrazeneca : thrombosis (2014-2015)</li> </ul>
Baron Esquivias Gonzalo	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer : Anticoagulation (2014)</li> <li>- Boehringer-Ingelheim : Anticoagulation (2014-2015)</li> <li>- Daiichi Sankyo : Anticoagulation (2014-2015)</li> <li>- Pfizer : Anticoagulation (2014-2015)</li> </ul>

## Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Baron Esquivias Gonzalo	<ul style="list-style-type: none"> <li>- Merck Sharp &amp; Dohme : Dyslipemia (2015)</li> </ul>
Baumgartner Helmut	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Actelion : Bosentan and Macicentan for PAH treatment in congenital heart disease (2014-2015)</li> <li>- St. Jude Medical : Occluders for shunt closure (ASD, PFO, PDA, VSD) (2014-2015)</li> <li>- Abbott : transcather mitral valve repair (Mitraclip) (2014-2015)</li> <li>- Edwards Lifesciences : transcatheter valve implantation (2014-2015)</li> <li>- Direct Flow Medical : transcatheter valve implantation (2014-2015)</li> <li>- Gore : Occluders for shunt closure (2015)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Actelion : Bosentan for PAH treatment in congenital heart disease (2014-2015)</li> <li>- St. Jude Medical : Occluders for shunt closure (ASD, PFO, PDA, VSD) (2014-2015)</li> <li>- Abbott : transcather mitral valve repair (Mitraclip) (2014-2015)</li> <li>- Edwards Lifesciences : transcatheter valve implantation (2014-2015)</li> <li>- Direct Flow Medical : transcatheter valve implantation (2014-2015)</li> <li>- Gore : Occluders for shunt closure (2015)</li> </ul>
Bax Jeroen	Nothing to be declared (2014-2015)
Bueno Hector	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer Healthcare : Aspirin, rivaroxaban (2014)</li> <li>- Menarini : Ranolazine (2014)</li> <li>- Novartis : Serelaxin (2014)</li> <li>- Pfizer : Apixaban (2014-2015)</li> <li>- Bristol Myers Squibb : Apixaban (2014-2015)</li> <li>- Sanofi Aventis : Clopidogrel (2014-2015)</li> <li>- Servier : ivabradine (2014-2015)</li> </ul>

## Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Bueno Hector	<ul style="list-style-type: none"> <li>- Daiichi Sankyo : Prasugrel (2014-2015)</li> <li>- Eli Lilly : Prasugrel (2014-2015)</li> <li>- Astra Zeneca : Ticagrelor (2014-2015)</li> <li>- Bayer Healthcare : Aspirin (2015)</li> <li>- Novartis : Serelaxin, LCZ696 (2015)</li> <li>- Ferrer Internacional : Trinomia (polypill) (2015)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : Ticagrelor (2015)</p> <p>E - Research funding (personal). - Astra Zeneca : Ticagrelor (2014-2015)</p>
Carerj Scipione	Nothing to be declared (2014-2015)
Erol Cetin	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : Hypertension (2014-2015)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Menarini : Hypertension (2014-2015)</p>
Fitzsimons Donna	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Amgen : FH Treatment options (2014) - Amgen : lipid management (2015)</p>
Gaemperli Oliver	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Biosensors : Stents (2014) - Abbott Vascular : MitraClip (2015) - Biosensors : Travel Grant to AsiaPCR 2015 (2015)</p>
Kirchhof Paulus	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Daiichi Sankyo : cardiovascular (2014) - Pfizer : cardiovascular (2014) - Bristol Myers Squibb : cardiovascular (2014)</p>

## Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Kirchhof Paulus	<ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : cardiovascular (2014-2015)</li> <li>- Medtronic : cardiovascular (2014-2015)</li> <li>- St Jude Medical : cardiovascular (2014-2015)</li> <li>- Sanofi Aventis : cardiovascular (2014-2015)</li> <li>- Meda pharma : cardiovascular (2014-2015)</li> <li>- Merck Sharp &amp; Dohme : cardiovascular (2014-2015)</li> <li>- Medscape : cardiovascular (2014-2015)</li> <li>- Astra Zeneca : cardiovascular (2015)</li> <li>- Servier : cardiovascular (2015)</li> <li>- Bayer Healthcare : cardiovascular (2015)</li> <li>- Bayer Vital : cardiovascular (2015)</li> <li>- Correvio : cardiovascular (2015)</li> <li>- Daiichi Sankyo Europe : cardiovascular (2015)</li> <li>- Bristol Myers Squibb Global : cardiovascular (2015)</li> <li>- Pfizer Global : cardiovascular (2015)</li> <li>- Pfizer Germany : cardiovascular (2015)</li> <li>D - Research funding (departmental or institutional).               <ul style="list-style-type: none"> <li>- Daiichi Sankyo : cardiovascular (2014-2015)</li> <li>- St Jude Medical : cardiovascular (2014-2015)</li> <li>- Sanofi Aventis : cardiovascular (2014-2015)</li> <li>- Meda pharma : cardiovascular (2014-2015)</li> <li>- British Heart Foundation : cardiovascular (2014-2015)</li> <li>- BMS / Pfizer alliance : cardiovascular (2014-2015)</li> </ul> </li> </ul>

## Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Kirchhof Paulus	<ul style="list-style-type: none"> <li>- Leducq Foundation : cardiovascular (2014-2015)</li> <li>- European Union FP7 : cardiovascular (2014-2015)</li> <li>- European Union horizon2020 : cardiovascular (2014-2015)</li> <li>- German Centre for Heart Research (DZHK, funded by German Ministry of Education and Research) : cardiovascular (2014-2015)</li> <li>- UK Medical Research Council : cardiovascular (2015)</li> </ul>
Kolh Philippe H	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Antiplatelet agents (2014-2015)</li> <li>- B.Braun : Surgical instruments (2014-2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Edwards Lifesciences : Cardiac valves (2014-2015)</li> <li>- Medtronic : Cardiac valves (2014-2015)</li> </ul>
Lancellotti Patrizio	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Menarini : nebivolol (2014)</li> <li>- St Jude Medical : Echo course (2015)</li> <li>- Servier : Imaging Ischemic disease (2015)</li> <li>- Boston Scientific : Sudden death (2015)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Boston Scientific : CRT (2014)</li> <li>- Servier : procoralan (2014)</li> <li>- Bayer : NOAC (2015)</li> </ul>
Lip Gregory Y H	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Medtronic : atrial fibrillation (2014-2015)</li> <li>- Biotronik : atrial fibrillation (2014-2015)</li> <li>- Boehringer-Ingelheim : atrial fibrillation, thrombosis (2014-2015)</li> <li>- Daiichi Sankyo : atrial fibrillation, thrombosis (2014-2015)</li> </ul>



## Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Lip Gregory Y H	<ul style="list-style-type: none"> <li>- Pfizer : atrial fibrillation, thrombosis (2014-2015)</li> <li>- Bayer Healthcare : atrial fibrillation, thrombosis (2014-2015)</li> <li>- Bristol Myers Squibb : atrial fibrillation, thrombosis (2014-2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Daiichi Sankyo : atrial fibrillation, thrombosis (2014-2015)</li> </ul>
Nihoyannopoulos Petros	Nothing to be declared (2014-2015)
Piepoli Massimo Francesco	<p>Nothing to be declared (2014)</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Servier : Cardiovascular Prevention and Rehabilitation Initiatives (2015)</li> <li>- Novartis : Heart Failure Prevention Initiatives (2015)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Novartis : Heart Failure Prevention Initiatives (2015)</li> </ul>
Ponikowski Piotr	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : acute coronary syndrome (2014)</li> <li>- Boehringer-Ingelheim : anticoagulant (2014)</li> <li>- Respicardia : anticoagulant (2014)</li> <li>- Johnson &amp; Johnson : heart failure (2014)</li> <li>- Pfizer : heart failure, anticoagulant (2014)</li> <li>- MSD : lipids (2014)</li> <li>- Abbott Vascular : devices (2014-2015)</li> <li>- Novartis : heart failure (2014-2015)</li> <li>- Cardiorentis : heart failure (2014-2015)</li> <li>- Bayer Healthcare : heart failure (2014-2015)</li> <li>- Vifor Pharma ltd : heart failure (2014-2015)</li> </ul>

## Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Ponikowski Piotr	<ul style="list-style-type: none"> <li>- CIBIEM : heart failure (2014-2015)</li> <li>- Servier : heart failure, coronary artery disease (2014-2015)</li> <li>- Amgen : heart failure, lipids (2014-2015)</li> <li>- Boehringer-Ingelheim : anticoagulant, diabetes (2015)</li> <li>- Respocardia : devices (2015)</li> <li>- BioControl : devices (2015)</li> <li>- DC Device : devices (2015)</li> <li>- Celladon : heart failure (2015)</li> <li>- Pfizer : lipids (2015)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : acute coronary syndrome (2014)</li> <li>- Vifor Pharma ltd : heart failure (2014)</li> <li>- MSD : lipids (2014)</li> <li>- Respocardia : anticoagulant (2014-2015)</li> <li>- Novartis : heart failure (2014-2015)</li> <li>- Cardioentis : heart failure (2014-2015)</li> <li>- Bayer Healthcare : heart failure (2014-2015)</li> <li>- CIBIEM : heart failure (2014-2015)</li> <li>- Servier : heart failure, coronary artery disease (2014-2015)</li> <li>- Amgen : heart failure, lipids (2014-2015)</li> <li>- BioControl : devices (2015)</li> <li>- DC Device : devices (2015)</li> <li>- Celladon : heart failure (2015)</li> </ul>

## Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Roffi Marco	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Johnson &amp; Johnson : coronary catheters (2014-2015)</li> <li>- Astra Zeneca : speaker fees related to the 2015 ESC NSTEMI GL (2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Biosensors : devices (2014-2015)</li> <li>- Boston Scientific : devices (2014-2015)</li> <li>- Medtronic : devices (2014-2015)</li> <li>- Biotronik : devices (2014-2015)</li> <li>- Abbott Vascular : devices (2014-2015)</li> <li>- Terumo Inc : devices (2015)</li> </ul>
Torbicki Adam	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bristol Myers Squibb : Pulmonary arterial hypertension (2014)</li> <li>- GlaxoSmithKline : pulmonary arterial hypertension - ambrisentan (2014)</li> <li>- Lilly : pulmonary arterial hypertension - ambrisentan (2014)</li> <li>- Actelion : pulmonary arterial hypertension - macitentan, selexipag (2014-2015)</li> <li>- Bayer Healthcare : pulmonary arterial hypertension - iloprost, riociguat, VTE - xarelto (2014-2015)</li> <li>- Teva Pharmaceutical Industries : anti-cancer treatment (2015)</li> <li>- Sanofi Aventis : anticoagulants (2015)</li> <li>- AOP Orphan Pharmaceuticals : pulmonary arterial hypertension (2015)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer Healthcare : Pulmonary hypertension (2014-2015)</li> </ul>
Vaz Carneiro Antonio	<p>Nothing to be declared (2015)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- AbbVie : Oncology (2014)</li> </ul>
Windecker Stephan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Eli Lilly : Antiplatelet therapy (2014)</li> </ul>

## Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Windecker Stephan	<ul style="list-style-type: none"> <li>- Bayer Healthcare : Antithrombotic drug (2014)</li> <li>- Abbott : Stent and Heartvalvetherapy (2014)</li> <li>- Biosensors : Stents (2014)</li> <li>- Boston Scientific : Stents (2014)</li> <li>- Astra Zeneca : Antiplatelet therapy (2014-2015)</li> <li>- Daiichi Sankyo : Antiplatelet therapy (2015)</li> <li>- Boston Scientific : Complex PCI (2015)</li> <li>- Sanofi Aventis : Managing Dyslipidemia (2015)</li> <li>D - Research funding (departmental or institutional).               <ul style="list-style-type: none"> <li>- Medicines Company : Antithrombotic therapy (2014)</li> <li>- Johnson &amp; Johnson : Catheters (2014)</li> <li>- Edwards Lifesciences : Heartvalves (2014)</li> <li>- St Jude Medical : OCT (2014)</li> <li>- Abbott : Stent (2014)</li> <li>- Biotronik : Stent (2014)</li> <li>- Boston Scientific : Stent and Heartvalves (2014)</li> <li>- Medtronic : Stent and Heartvalves (2014)</li> <li>- Sorin Group : Electrophysiology (2015)</li> <li>- Biotronik : Electrophysiology (2015)</li> <li>- Johnson &amp; Johnson : Electrophysiology and PCI (2015)</li> <li>- Guerbet : Imaging (2015)</li> <li>- Novartis : IMP (2015)</li> <li>- Actelion : IMP (2015)</li> </ul> </li> </ul>

## Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Windecker Stephan	<ul style="list-style-type: none"> <li>- Medicines Company : IMP (2015)</li> <li>- Merck Sharp &amp; Dohme : IMP (2015)</li> <li>- St Jude Medical : PCI (2015)</li> <li>- Abbott : PCI and Structural Heart Disease (2015)</li> <li>- Boston Scientific : Structural Heart Disease (2015)</li> <li>- Edwards Lifesciences : Structural Heart Disease (2015)</li> <li>- Symetis SA : Structural Heart Disease (2015)</li> <li>- Medtronic : Structural Heat Disease (2015)</li> </ul>
Zamorano Gomez Jose Luis	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Philips : 3D echo (2014)</li> <li>- Toshiba medical imaging : fusion imaging 3D echo CT (2014)</li> <li>- Astra Zeneca : Speaker fee for 1 talk in 2014 (2014)</li> <li>- MSD : CV risk factors (2014-2015)</li> <li>- Abbott : Lecturing (2015)</li> <li>- Pfizer : Lecturing (2015)</li> <li>- Sorin Group : Respicardia echo protocol (2015)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Siemens Healthcare : 3d echo software and free style echo (2014-2015)</li> <li>- Toshiba medical imaging : Fusion Imaging (2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Amgen : Clinical trial (2014-2015)</li> <li>- Novartis : Clinical trial (2014-2015)</li> <li>- Ikaria : Clinical trial (2014-2015)</li> </ul>